Eli Lilly and Company (LLY)
Eli Lilly releases new form of weight loss drug Zepbound for half the price to boost access, supply
Eli Lilly released a new form of its weight loss drug Zepbound for roughly half its usual monthly list price to increase access for patients without insurance coverage for the highly popular injection. The move also aims to expand the U.S. supply of Zepbound amid soaring demand and ensure patients are safely accessing the treatment as cheaper copycat versions of the drug gain traction.
Buy 4 Top-Ranked Stocks to Play Likely Earnings Beat
Top-ranked stocks Norwegian Cruise Line (NCLH), Eli Lilly (LLY), The Progressive (PGR) and Fortinet (FTNT) are likely to beat on earnings in their upcoming releases.
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
Mounjaro Scores Yet Another Win: Why Eli Lilly Is Still a Buy
Eli Lilly's crown jewel performed well in another pivotal clinical trial. The medicine's potential looks even more attractive than it already did.
Prediction: These Will Be the Best-Performing S&P 500 Stocks of 2024
2024's best-performing S&P 500 stock so far should keep its top spot with a blow-out quarterly update this month. The No. 2 S&P 500 stock should continue to enjoy a massive tailwind throughout the rest of the year.
Eli Lilly's Growth Rate Is Fantastic, but This Number Is Even Better
Eli Lilly's sales rose by 36% last quarter to $11.3 billion. The company's low cost of sales has boosted its bottom line at a much higher rate.
Lilly (LLY) Up 3% on Obesity Drug Cutting Diabetes Risk
Eli Lilly (LLY) reports data from a late-stage study that found that long-term treatment with Zepbound reduces the risk of progression to type 2 diabetes by 94%.
Watch These Eli Lilly Price Levels as Stock Sets Record High on Trial Results
Eli Lilly (LLY) shares set a record high on Tuesday after announcing that clinical trials of tirzepatide, the medicine used in the company's diabetes drug Mounjaro and injectable weight loss treatment Zepbound, significantly reduced the risk of developing type 2 diabetes in patients.
Eli Lilly Stock Could Soar to $1,150, According to a Wall Street Analyst. Is It a Buy at Around $945?
Bank of America's price target for Eli Lilly implies a gain of about 25% from the stock's recent closing price. Eli Lilly's blockbuster weight management drug is gaining market share at a rapid pace.
Eli Lilly's Zepbound reduces type 2 diabetes risk, study shows
Eli Lilly announced results of a study in which weekly shots of tirzepatide injections significantly reduced the risk of progression to type 2 diabetes by 94% among certain adults.
Why Eli Lilly Topped the Market on Tuesday
The pharmaceutical giant has been investigating its Zepbound/Mounjaro drug for various indications. It performed very well in its latest diabetes and weight loss study.
Eli Lilly: Tirzepatide's Winning Streak Continues
Eli Lilly's key growth product tirzepatide (Mounjaro/Zepbound) continues to deliver on both fronts. Increased supply visibility led to a $3 billion increase in the full-year total revenue guidance range. After strong Q2 results, Eli Lilly reported positive long-term data from the SURMOUNT-1 trial, showing long-term treatment with tirzepatide significantly reduced the risk of onset of type 2 diabetes.
